Exelixis Inc (EXEL) 1.40 $EXEL
Array BioPharma Advances To All Systems Go, Collects $85 Million
Clinically Sound Investor - at Seeking Alpha - Fri Dec 12, 8:13AM CST
ARRY: 4.86 (-0.04), EXEL: 1.40 (unch)
Exelixis' COMET-2 Failure And A Discussion Of Potential Future Cash Flow
Daniel Ward - at Seeking Alpha - Wed Dec 03, 2:51PM CST
EXEL: 1.40 (unch)
Exelixis Shares Down on COMET-2 Study Results on Cabozantinib - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 02, 1:29PM CST
Shares of Exelixis, Inc. (EXEL) dropped 10.2% after the company announced that the trial COMET-2 on cabozantinib did not meet its primary endpoint.
VRX: 138.71 (-0.18), PSTI: 2.60 (+0.01), EXEL: 1.40 (unch)
Is Exelixis, Inc. Stock Doomed?
George Budwell, The Motley Fool - Motley Fool - Tue Dec 02, 7:14AM CST
Biotech stocks are infamous for their volatile ways -- shooting higher one minute, only to crater the next. After a biotech crashes, investors should always assess their options going forward. Sometimes a marked sell-off represents a compelling...
EXEL: 1.40 (unch)
Update: Exelixis Announces Final COMET-2 Data- What Can Shareholders Do?
Christopher F. Davis - at Seeking Alpha - Mon Dec 01, 12:31PM CST
EXEL: 1.40 (unch)
Future of Exelixis Cancer Drug Dims Further With Second Failed Prostate Cancer Study
at The Street - Mon Dec 01, 10:37AM CST
All too often, promising results from phase II studies don't pan out when larger, confirmatory phase III studies are conducted. That's exactly what happened to Exelixis.
EXEL: 1.40 (unch)
Exelixis Down 15.1%, Shares Slide into the Red (EXEL)
Comtex SmarTrend(R) - Mon Dec 01, 10:08AM CST
Exelixis (NASDAQ:EXEL) is one of today's worst performing low-priced stocks, down 15.1% to $1.41 on 2.0x average daily volume. Thus far today, Exelixis has traded 3.8 million shares, vs. average volume of 1.9 million shares per day. The stock has underperformed the Dow (-15.1% to the Dow's -0.4%) and underperformed the S&P 500 (-15.1% to the S&P's -0.9%) during today's trading.
EXEL: 1.40 (unch)
Exelixis drops 15% after prostate cancer drug candidate fails Phase 3
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 9:14AM CST
EXEL: 1.40 (unch)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 8:13AM CST
KOG: 6.56 (-0.39), HK: 2.01 (-0.09), FRO: 2.25 (+0.62), ISR: 1.62 (-0.02), EOX: 0.97 (-0.31), DWA: 21.75 (+0.04), SSE: 4.58 (-0.12), CANF: 3.49 (+0.03), VNET: 15.72 (-0.78), GRPN: 7.22 (-0.04), POZN: 9.12 (-0.08), ONNN: 9.65 (-0.12), EXEL: 1.40 (unch)
Exelixis Announces Results from the COMET-2 Pivotal Phase 3 Trial of Cabozantinib in Men With Metastatic Castration-Resistant Prostate Cancer
Business Wire - Mon Dec 01, 7:01AM CST
Exelixis, Inc. (NASDAQ:EXEL) today announced top-line results from the final analysis of COMET-2, a randomized, double-blind, controlled trial of cabozantinib in men with metastatic castration-resistant prostate cancer (mCRPC) who are suffering from moderate to severe pain despite optimized narcotic medication, and whose disease has progressed following treatment with docetaxel as well as abiraterone and/or enzalutamide. The trial did not meet its primary endpoint of alleviation of bone pain, as determined by comparing the percentage of patients in the two treatment arms who achieved a pain response at Week 6 that was confirmed at Week 12 without increase in narcotic medication. Fifteen percent of patients in the cabozantinib arm reported a pain response, compared to 17 percent of patients in the control arm receiving mitoxantrone/ prednisone. The difference in pain response between the arms was not statistically significant. The safety profile of cabozantinib in the trial was consistent with that observed in previous studies in mCRPC.
EXEL: 1.40 (unch)
Exelixis to Present at the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, December 2
Business Wire - Tue Nov 25, 3:05PM CST
Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey, Ph.D., the company's president and chief executive officer, will provide an overview of the company at the Piper Jaffray 26th Annual Healthcare Conference taking place December 2-3 in New York. The Exelixis presentation is scheduled for 1:30 p.m. EST/10:30 a.m. PST on Tuesday, December 2, 2014.
EXEL: 1.40 (unch)
Exelixis: Why This Company Could Become The Next Dendreon
Daniel Ward - at Seeking Alpha - Tue Nov 18, 11:54AM CST
EXEL: 1.40 (unch)
Today's Review on Biotech Equities - Exelixis, Geron, Tekmira Pharma, Galena Biopharma, and XOMA
PR Newswire - Tue Nov 18, 8:00AM CST
Investor-Edge has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), Geron Corporation (NASDAQ: GERN), Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR), Galena Biopharma Inc. (NASDAQ: GALE), and XOMA Corporation (NASDAQ: XOMA). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, November 17, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,647.75, up 0.07% and the NASDAQ Composite closed at 4,671.00, down 0.37%. The S&P 500 finished the session 0.07% higher at 2,041.32. During the trading session, four out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 781.08, up 0.49%, with the index advancing 9.06% in the previous three months. Register for your complimentary reports on these five stocks at:
DRNA: 12.88 (+1.19), GERN: 3.24 (+0.01), TKMR: 14.28 (+0.19), GALE: 1.69 (unch), XOMA: 4.68 (-0.02), EXEL: 1.40 (unch)
Update: Exelixis Announces Very Positive Phase 1 Trial Data
Christopher F. Davis - at Seeking Alpha - Tue Nov 18, 12:28AM CST
EXEL: 1.40 (unch)
Biotech Weekly: Here Come The Institutional Holdings Updates
Daniel Ward - at Seeking Alpha - Mon Nov 17, 7:31AM CST
LOXO: 11.13 (-0.92), TRGT: 2.46 (-0.01), BOTA: 2.32 (+0.05), XBI: 183.73 (-0.31), IBB: 306.10 (-3.95), BIOS: 5.91 (-0.12), RGDO: 0.89 (+0.02), EXEL: 1.40 (unch), AMPH: 11.73 (+0.02)
Exelixis Announces Positive Preliminary Data From an Investigator-Sponsored Phase 1 Trial of XL888 and Vemurafenib
Business Wire - Sun Nov 16, 3:20AM CST
--- Investigators Plan Phase 1b Triple-combination Trial of XL888, Vemurafenib, and Cobimetinib -
EXEL: 1.40 (unch)
Exelixis to Present at the Stifel 2014 Healthcare Conference on Tuesday, November 18
Business Wire - Tue Nov 11, 3:40PM CST
Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey, Ph.D., the company's president and chief executive officer, will provide an overview of the company at the Stifel 2014 Healthcare Conference taking place November 18-19 in New York. The Exelixis presentation is scheduled for 9:10 a.m. EST/6:10 a.m. PST on Tuesday, November 18, 2014.
EXEL: 1.40 (unch)
Global Papillary Thyroid Cancer therapeutics Pipeline Report H2 2014 - Analysis of 6 Companies & 8 Drug Profiles
M2 - Tue Nov 11, 3:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/lcrf6q/papillary_thyroid) has announced the addition of the "Papillary Thyroid Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Papillary Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Papillary Thyroid Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - GlaxoSmithKline plc - Plexxikon Inc. - Novartis AG - Exelixis, Inc. - Deciphera Pharmaceuticals, LLC Drug Profiles - vandetanib - everolimus - cabozantinib s-malate - dabrafenib mesylate - rebastinib tosylate - PLX-7486 - CLM-3 - CLM-29 For more information visit http://www.researchandmarkets.com/research/lc...ry_thyroid
AZN: 71.80 (-1.80), GSK: 42.42 (-0.93), NVS: 93.52 (-0.82), EXEL: 1.40 (unch)
Global Relapsed Multiple Myeloma Therapeutics Pipeline Report H2 2014 - Analysis of 43 Companies & 71 Drug Profiles
M2 - Mon Nov 10, 10:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/hfth47/relapsed_multiple) has announced the addition of the "Relapsed Multiple Myeloma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Johnson & Johnson - F. Hoffmann-La Roche Ltd. - Sanofi - Eli Lilly and Company - GlaxoSmithKline plc - Biotest AG - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - Pfizer Inc. - Astex Pharmaceuticals, Inc. - Exelixis, Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Immunomedics, Inc. - Cellectar Biosciences, Inc. - Oncolytics Biotech Inc. - Patrys Limited - Curis, Inc. - Pharmacyclics, Inc. - Array BioPharma Inc. - MorphoSys AG - Sevion Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Chroma Therapeutics Ltd. - Acceleron Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/hf...d_multiple
CLRB: 3.09 (+0.09), CRIS: 1.18 (+0.03), IMMU: 4.58 (-0.09), PCYC: 132.65 (-2.34), ONCY: 0.61 (+0.03), PFE: 30.95 (-0.70), LLY: 69.55 (-2.06), BMY: 58.75 (-0.93), GSK: 42.42 (-0.93), JNJ: 104.43 (-2.29), SNTA: 2.87 (+0.04), NVS: 93.52 (-0.82), XLRN: 41.77 (+0.29), ARRY: 4.86 (-0.04), CELGZ: 3.51 (-0.03), EXEL: 1.40 (unch)
Update: Exelixis Reports Q3 Earnings - Impact To My Thesis
Christopher F. Davis - at Seeking Alpha - Fri Nov 07, 3:42AM CST
EXEL: 1.40 (unch)
Array BioPharma Advances To All Systems Go, Collects $85 Million
Clinically Sound Investor - at Seeking Alpha - Fri Dec 12, 8:13AM CST
ARRY: 4.86 (-0.04), EXEL: 1.40 (unch)
Exelixis' COMET-2 Failure And A Discussion Of Potential Future Cash Flow
Daniel Ward - at Seeking Alpha - Wed Dec 03, 2:51PM CST
EXEL: 1.40 (unch)
Exelixis Shares Down on COMET-2 Study Results on Cabozantinib - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 02, 1:29PM CST
Shares of Exelixis, Inc. (EXEL) dropped 10.2% after the company announced that the trial COMET-2 on cabozantinib did not meet its primary endpoint.
VRX: 138.71 (-0.18), PSTI: 2.60 (+0.01), EXEL: 1.40 (unch)
Is Exelixis, Inc. Stock Doomed?
George Budwell, The Motley Fool - Motley Fool - Tue Dec 02, 7:14AM CST
Biotech stocks are infamous for their volatile ways -- shooting higher one minute, only to crater the next. After a biotech crashes, investors should always assess their options going forward. Sometimes a marked sell-off represents a compelling...
EXEL: 1.40 (unch)
Update: Exelixis Announces Final COMET-2 Data- What Can Shareholders Do?
Christopher F. Davis - at Seeking Alpha - Mon Dec 01, 12:31PM CST
EXEL: 1.40 (unch)
Future of Exelixis Cancer Drug Dims Further With Second Failed Prostate Cancer Study
at The Street - Mon Dec 01, 10:37AM CST
All too often, promising results from phase II studies don't pan out when larger, confirmatory phase III studies are conducted. That's exactly what happened to Exelixis.
EXEL: 1.40 (unch)
Exelixis Down 15.1%, Shares Slide into the Red (EXEL)
Comtex SmarTrend(R) - Mon Dec 01, 10:08AM CST
Exelixis (NASDAQ:EXEL) is one of today's worst performing low-priced stocks, down 15.1% to $1.41 on 2.0x average daily volume. Thus far today, Exelixis has traded 3.8 million shares, vs. average volume of 1.9 million shares per day. The stock has underperformed the Dow (-15.1% to the Dow's -0.4%) and underperformed the S&P 500 (-15.1% to the S&P's -0.9%) during today's trading.
EXEL: 1.40 (unch)
Exelixis drops 15% after prostate cancer drug candidate fails Phase 3
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 9:14AM CST
EXEL: 1.40 (unch)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 8:13AM CST
KOG: 6.56 (-0.39), HK: 2.01 (-0.09), FRO: 2.25 (+0.62), ISR: 1.62 (-0.02), EOX: 0.97 (-0.31), DWA: 21.75 (+0.04), SSE: 4.58 (-0.12), CANF: 3.49 (+0.03), VNET: 15.72 (-0.78), GRPN: 7.22 (-0.04), POZN: 9.12 (-0.08), ONNN: 9.65 (-0.12), EXEL: 1.40 (unch)
Exelixis Announces Results from the COMET-2 Pivotal Phase 3 Trial of Cabozantinib in Men With Metastatic Castration-Resistant Prostate Cancer
Business Wire - Mon Dec 01, 7:01AM CST
Exelixis, Inc. (NASDAQ:EXEL) today announced top-line results from the final analysis of COMET-2, a randomized, double-blind, controlled trial of cabozantinib in men with metastatic castration-resistant prostate cancer (mCRPC) who are suffering from moderate to severe pain despite optimized narcotic medication, and whose disease has progressed following treatment with docetaxel as well as abiraterone and/or enzalutamide. The trial did not meet its primary endpoint of alleviation of bone pain, as determined by comparing the percentage of patients in the two treatment arms who achieved a pain response at Week 6 that was confirmed at Week 12 without increase in narcotic medication. Fifteen percent of patients in the cabozantinib arm reported a pain response, compared to 17 percent of patients in the control arm receiving mitoxantrone/ prednisone. The difference in pain response between the arms was not statistically significant. The safety profile of cabozantinib in the trial was consistent with that observed in previous studies in mCRPC.
EXEL: 1.40 (unch)
Exelixis to Present at the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, December 2
Business Wire - Tue Nov 25, 3:05PM CST
Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey, Ph.D., the company's president and chief executive officer, will provide an overview of the company at the Piper Jaffray 26th Annual Healthcare Conference taking place December 2-3 in New York. The Exelixis presentation is scheduled for 1:30 p.m. EST/10:30 a.m. PST on Tuesday, December 2, 2014.
EXEL: 1.40 (unch)
Exelixis: Why This Company Could Become The Next Dendreon
Daniel Ward - at Seeking Alpha - Tue Nov 18, 11:54AM CST
EXEL: 1.40 (unch)
Today's Review on Biotech Equities - Exelixis, Geron, Tekmira Pharma, Galena Biopharma, and XOMA
PR Newswire - Tue Nov 18, 8:00AM CST
Investor-Edge has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), Geron Corporation (NASDAQ: GERN), Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR), Galena Biopharma Inc. (NASDAQ: GALE), and XOMA Corporation (NASDAQ: XOMA). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, November 17, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,647.75, up 0.07% and the NASDAQ Composite closed at 4,671.00, down 0.37%. The S&P 500 finished the session 0.07% higher at 2,041.32. During the trading session, four out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 781.08, up 0.49%, with the index advancing 9.06% in the previous three months. Register for your complimentary reports on these five stocks at:
DRNA: 12.88 (+1.19), GERN: 3.24 (+0.01), TKMR: 14.28 (+0.19), GALE: 1.69 (unch), XOMA: 4.68 (-0.02), EXEL: 1.40 (unch)
Update: Exelixis Announces Very Positive Phase 1 Trial Data
Christopher F. Davis - at Seeking Alpha - Tue Nov 18, 12:28AM CST
EXEL: 1.40 (unch)
Biotech Weekly: Here Come The Institutional Holdings Updates
Daniel Ward - at Seeking Alpha - Mon Nov 17, 7:31AM CST
LOXO: 11.13 (-0.92), TRGT: 2.46 (-0.01), BOTA: 2.32 (+0.05), XBI: 183.73 (-0.31), IBB: 306.10 (-3.95), BIOS: 5.91 (-0.12), RGDO: 0.89 (+0.02), EXEL: 1.40 (unch), AMPH: 11.73 (+0.02)
Exelixis Announces Positive Preliminary Data From an Investigator-Sponsored Phase 1 Trial of XL888 and Vemurafenib
Business Wire - Sun Nov 16, 3:20AM CST
--- Investigators Plan Phase 1b Triple-combination Trial of XL888, Vemurafenib, and Cobimetinib -
EXEL: 1.40 (unch)
Exelixis to Present at the Stifel 2014 Healthcare Conference on Tuesday, November 18
Business Wire - Tue Nov 11, 3:40PM CST
Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey, Ph.D., the company's president and chief executive officer, will provide an overview of the company at the Stifel 2014 Healthcare Conference taking place November 18-19 in New York. The Exelixis presentation is scheduled for 9:10 a.m. EST/6:10 a.m. PST on Tuesday, November 18, 2014.
EXEL: 1.40 (unch)
Global Papillary Thyroid Cancer therapeutics Pipeline Report H2 2014 - Analysis of 6 Companies & 8 Drug Profiles
M2 - Tue Nov 11, 3:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/lcrf6q/papillary_thyroid) has announced the addition of the "Papillary Thyroid Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Papillary Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Papillary Thyroid Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - GlaxoSmithKline plc - Plexxikon Inc. - Novartis AG - Exelixis, Inc. - Deciphera Pharmaceuticals, LLC Drug Profiles - vandetanib - everolimus - cabozantinib s-malate - dabrafenib mesylate - rebastinib tosylate - PLX-7486 - CLM-3 - CLM-29 For more information visit http://www.researchandmarkets.com/research/lc...ry_thyroid
AZN: 71.80 (-1.80), GSK: 42.42 (-0.93), NVS: 93.52 (-0.82), EXEL: 1.40 (unch)
Global Relapsed Multiple Myeloma Therapeutics Pipeline Report H2 2014 - Analysis of 43 Companies & 71 Drug Profiles
M2 - Mon Nov 10, 10:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/hfth47/relapsed_multiple) has announced the addition of the "Relapsed Multiple Myeloma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Johnson & Johnson - F. Hoffmann-La Roche Ltd. - Sanofi - Eli Lilly and Company - GlaxoSmithKline plc - Biotest AG - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - Pfizer Inc. - Astex Pharmaceuticals, Inc. - Exelixis, Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Immunomedics, Inc. - Cellectar Biosciences, Inc. - Oncolytics Biotech Inc. - Patrys Limited - Curis, Inc. - Pharmacyclics, Inc. - Array BioPharma Inc. - MorphoSys AG - Sevion Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Chroma Therapeutics Ltd. - Acceleron Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/hf...d_multiple
CLRB: 3.09 (+0.09), CRIS: 1.18 (+0.03), IMMU: 4.58 (-0.09), PCYC: 132.65 (-2.34), ONCY: 0.61 (+0.03), PFE: 30.95 (-0.70), LLY: 69.55 (-2.06), BMY: 58.75 (-0.93), GSK: 42.42 (-0.93), JNJ: 104.43 (-2.29), SNTA: 2.87 (+0.04), NVS: 93.52 (-0.82), XLRN: 41.77 (+0.29), ARRY: 4.86 (-0.04), CELGZ: 3.51 (-0.03), EXEL: 1.40 (unch)
Update: Exelixis Reports Q3 Earnings - Impact To My Thesis
Christopher F. Davis - at Seeking Alpha - Fri Nov 07, 3:42AM CST
EXEL: 1.40 (unch)
